Literature DB >> 25434391

The role of cancer stem cells in glioblastoma.

Swetha J Sundar1, Jason K Hsieh, Sunil Manjila, Justin D Lathia, Andrew Sloan.   

Abstract

Recurrence in glioblastoma is nearly universal, and its prognosis remains dismal despite significant advances in treatment over the past decade. Glioblastoma demonstrates considerable intratumoral phenotypic and molecular heterogeneity and contains a population of cancer stem cells that contributes to tumor propagation, maintenance, and treatment resistance. Cancer stem cells are functionally defined by their ability to self-renew and to differentiate, and they constitute the diverse hierarchy of cells composing a tumor. When xenografted into an appropriate host, they are capable of tumorigenesis. Given the critical role of cancer stem cells in the pathogenesis of glioblastoma, research into their molecular and phenotypic characteristics is a therapeutic priority. In this review, the authors discuss the evolution of the cancer stem cell model of tumorigenesis and describe the specific role of cancer stem cells in the pathogenesis of glioblastoma and their molecular and microenvironmental characteristics. They also discuss recent clinical investigations into targeted therapies against cancer stem cells in the treatment of glioblastoma.

Entities:  

Keywords:  CSC = cancer stem cell; GBM = glioblastoma; HIF = hypoxia-inducible factor; NSC = neural stem cell; OS = overall survival; PFS = progression-free survival; SHH = sonic hedgehog; TGF-β = transforming growth factor–β; TMZ = temozolomide; VEGF = vascular endothelial growth factor; VEGFC = VEGF C; cancer stem cells; clinical trials; glioblastoma; pathophysiology; treatment

Mesh:

Year:  2014        PMID: 25434391     DOI: 10.3171/2014.9.FOCUS14494

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  49 in total

1.  Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients.

Authors:  Candace M Howard; Jagan Valluri; Anthony Alberico; Terrence Julien; Rida Mazagri; Robert Marsh; Hoyt Alastair; Antonio Cortese; Michael Griswold; Wanmei Wang; Krista Denning; Linda Brown; Pier Paolo Claudio
Journal:  Transl Oncol       Date:  2017-02-12       Impact factor: 4.243

2.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions.

Authors:  Danh Truong; Roberto Fiorelli; Eric S Barrientos; Ernesto Luna Melendez; Nader Sanai; Shwetal Mehta; Mehdi Nikkhah
Journal:  Biomaterials       Date:  2018-07-30       Impact factor: 12.479

Review 4.  Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.

Authors:  Andrew W Smith; Minesh P Mehta; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2016-04-23       Impact factor: 4.130

5.  CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia- versus normoxia-microenviroment.

Authors:  Guobin Zhang; Yunsheng Zhang; Sen Cheng; Zhen Wu; Fusheng Liu; Junting Zhang
Journal:  J Neurooncol       Date:  2017-09-25       Impact factor: 4.130

6.  Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins.

Authors:  Vashendriya V V Hira; Jill R Wormer; Hala Kakar; Barbara Breznik; Britt van der Swaan; Renske Hulsbos; Wikky Tigchelaar; Zbynek Tonar; Mohammed Khurshed; Remco J Molenaar; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2018-01-03       Impact factor: 2.479

7.  Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.

Authors:  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

8.  Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.

Authors:  Eui Hyun Kim; Ji-Hyun Lee; Yoonjee Oh; Ilkyoo Koh; Jin-Kyoung Shim; Junseong Park; Junjeong Choi; Mijin Yun; Jeong Yong Jeon; Yong Min Huh; Jong Hee Chang; Sun Ho Kim; Kyung-Sup Kim; Jae-Ho Cheong; Pilnam Kim; Seok-Gu Kang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

Review 9.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 10.  Adhering towards tumorigenicity: altered adhesion mechanisms in glioblastoma cancer stem cells.

Authors:  Soumya M Turaga; Justin D Lathia
Journal:  CNS Oncol       Date:  2016-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.